Early Cancer Relapse Detection - Molecular Residual Disease (MRD) Monitoring

A serial ctDNA blood test designed to detect minimal residual disease (MRD). It monitors treatment response and identifies early relapse signs long before they are visible on conventional imaging or clinical scans.